Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - VEGF Inhibitor Study Indication Phase NCT03481634 KESTREL (CRTH258B2301) Diabetic eye disease Phase 3 Patients 534 Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 3 mg/50 μL Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2mg/50 uL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q4-2020 (actual); Final: Q4-2021 Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 NCT03481660 KITE (CRTH258B2302) Diabetic eye disease Phase 3 356 Change from baseline in best-corrected visual acuity (BCVA) Brolucizumab (RTH258) 6 mg/50 μL Aflibercept 2 mg/50 μL Patients with visual impairment due to diabetic macular edema (DME) Primary: Q3-2020 (actual); Final: Q3-2021 (actual). Brown et al., presented at ARVO May 2021 Manuscript submission H2 2021 97 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation